2021
DOI: 10.3748/wjg.v27.i22.3130
|View full text |Cite
|
Sign up to set email alerts
|

High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study

Abstract: BACKGROUND One third of coronavirus disease 2019 (COVID-19) patients have gastrointestinal symptoms. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA has been detected in stool samples of approximately 50% of COVID-19 individuals. Fecal calprotectin is a marker of gastrointestinal inflammation in the general population. AIM To investigate if fecal calprotectin correlates with SARS-CoV-2 intestinal shedding in COVID-19 patients with pneumonia. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 16 publications
(11 citation statements)
references
References 26 publications
0
10
1
Order By: Relevance
“…This suggests the potential risk of fecal-oral transmission and raises the question of whether this prolonged delayed clearance in the gut system causes persistent gastrointestinal inflammation or becomes one of the long COVID-19 manifestations that needs further investigation. 27 There were several limitations of this study. The monocentric study with a small sample of this study might not be enough to represent the general population.…”
Section: Discussionmentioning
confidence: 91%
“…This suggests the potential risk of fecal-oral transmission and raises the question of whether this prolonged delayed clearance in the gut system causes persistent gastrointestinal inflammation or becomes one of the long COVID-19 manifestations that needs further investigation. 27 There were several limitations of this study. The monocentric study with a small sample of this study might not be enough to represent the general population.…”
Section: Discussionmentioning
confidence: 91%
“…The authors did not detect any differences in FC concentrations between patients with and without diarrhea. However, the patients with SARS-CoV-2 RNA detected in fecal samples had higher FC (74 vs. 39 mg/kg, p < 0.001), lower neutrophil counts (5550 vs. 4390 cell/µL, p < 0.035), and higher D-Dimer (723 vs. 580 ng/mLFEU) [40]. On the contrary, Britton et al did not find any correlation or difference in FC concentrations between patients stratified by gastrointestinal symptoms or detection of fecal viral-RNA [38].…”
Section: Fecal Calprotectin and Covid-19mentioning
confidence: 91%
“…The downside of this strategy includes the disturbance of the fCAL level by several confounding factors. Approximately 20% of healthy participants, patients using non‐steroidal anti‐inflammatory drugs (NSAIDs), body mass index (BMI) >25 kg/m 2 and even in the groups with coronavirus disease 19 (COVID‐19) have statistically significantly higher fCAL levels 15,16 . The users of anti‐TNF antibodies, including infliximab, adalimumab, golimumab had significantly lower fCAL compared to patients without therapy 11 …”
Section: Fecal Calprotectinmentioning
confidence: 99%